Low Moor

Researchers are evaluating the safety and effects of disitamab vedotin for treating adults with advanced breast cancer that is difficult to treat and has spread in the body. The study focuses on patients whose tumors express HER2 and who have previously received treatment for their advanced breast cancer. This open-label, non-randomized study is sponsored by Pfizer and includes multiple groups based on HER2 and hormone receptor status. All participants will receive disitamab vedotin as an intravenous infusion every two weeks at the study clinic. The treatment continues until either the participant or doctor decides to stop, which may be due to cancer progression, side effects, or personal choice. After stopping treatment, participants will have follow-up visits about every six weeks, followed by phone calls every twelve weeks to monitor their health. During the study, participants will attend visits every two weeks for treatment and assessments. Researchers will evaluate tumor response, duration of response, disease control, progression-free survival, overall survival, and drug levels in the blood. Safety will be monitored for up to two years, and participants can expect regular checkups and tests throughout the study period, which may last up to three years.

Researchers are evaluating whether adding tucatinib to trastuzumab and mFOLFOX6 works better than the current standard treatments for people with HER2 positive metastatic colorectal cancer. This study focuses on participants whose cancer has spread or cannot be removed by surgery. The trial also monitors side effects that might occur from taking these drug combinations. Participants are randomly assigned to one of two groups. One group receives tucatinib taken orally twice daily along with trastuzumab given intravenously every three weeks and mFOLFOX6 chemotherapy every two weeks. The other group receives standard care, which includes mFOLFOX6 alone or combined with bevacizumab or cetuximab given by intravenous infusion. The study treatments continue as per the assigned schedule. During the study, participants undergo regular scans and evaluations to measure progression-free survival and other outcomes up to approximately three years. Researchers also assess overall survival, response rates, duration of response, quality of life, and side effects for up to about six years. Safety monitoring continues for around one year after the last treatment. Participants are closely followed to understand the impact of these treatments on their cancer and well-being.

Researchers are studying a new medicine called PF-08634404 to see how well it works for adults with colorectal cancer that has spread to other parts of the body. This trial aims to find out if combining PF-08634404 with approved chemotherapy helps compared to using another approved medicine, Bevacizumab, combined with chemotherapy. The study is a phase 3, double-blind, randomized trial focused on treatment-nafve participants with metastatic colorectal cancer. Participants will be randomly assigned to one of two groups: one group will receive PF-08634404 plus chemotherapy, and the other will receive Bevacizumab plus chemotherapy. Both treatments are given through intravenous (IV) infusions at a clinical site. Treatments are given in cycles, and participants can continue treatment as long as it is helping and side effects are manageable. During the study, participants will have regular visits for treatment, health checks, and tests. After stopping treatment, there will be a final visit about 30 to 37 days later to evaluate health and side effects. Follow-up will continue every 12 weeks by phone, in person, or by reviewing health records. The study is expected to last about 33 months per participant. Researchers will measure outcomes like progression-free survival and overall survival over approximately 4 years, along with response rates, duration of response, quality of life, and safety assessments.

Researchers are evaluating a new medicine called PF-08634404 for adults with locally advanced or metastatic urothelial cancer, a type of bladder cancer that has spread to nearby tissues or other parts of the body. The study aims to assess the safety, effectiveness, how the medicine moves through the body, and its impact on cancer-related markers. This is an open-label, interventional trial sponsored by Pfizer. The study includes two groups: Cohort A consists of participants who have already received treatment for their cancer and will receive PF-08634404 alone through intravenous infusion. Cohort B includes participants who have not had prior treatment and will receive PF-08634404 combined with another cancer medicine called enfortumab vedotin, also through IV infusion. Treatment will continue as long as it is helpful and side effects are manageable. Before starting, participants undergo screening to confirm eligibility. During the study, regular visits will include treatment administration, health checks, and tests such as scans to monitor cancer response. Researchers will measure outcomes like confirmed objective response rate, side effects, duration of response, progression-free survival, and overall survival over up to three years. Participants may continue treatment even if cancer worsens, with agreement from their doctor and the study sponsor. Safety monitoring will continue for 90 days after treatment ends.

Researchers are evaluating a new medicine called PF-08634404 in adults with advanced Renal Cell Carcinoma (RCC), a type of kidney cancer that has spread locally or to other parts of the body. The study aims to assess the safety of PF-08634404 when given alone or in combination with other anticancer drugs and to observe how this cancer responds to these treatments. Participants must be adults with locally advanced or metastatic RCC who have not received prior treatment for their advanced kidney cancer. Participants will be randomly assigned to one of three groups: receiving PF-08634404 alone through intravenous (IV) infusion, PF-08634404 combined with ipilimumab, or PF-08634404 combined with axitinib. All treatments are administered by IV infusions at clinical study sites, where medical staff will monitor participants during and after each visit. The study includes phases 1b and 2 to evaluate safety and efficacy over time. During the study, participants will undergo regular assessments including measuring tumor response using RECIST criteria, monitoring for side effects and adverse events, and evaluating survival and progression-free survival for up to approximately three years. Laboratory tests, pharmacokinetics, and immunogenicity will also be tracked. The study will continue monitoring participants for safety up to 90 days after the last treatment dose, with the total participation duration lasting about three years.

Researchers are studying a new medicine called PF-08634404 in combination with chemotherapy for adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing lung cancer that has spread widely in the body. The study aims to learn how well PF-08634404 works and how safe it is when given with chemotherapy compared to another approved treatment, atezolizumab plus chemotherapy. The study is a global phase 2/3 randomized trial sponsored by Pfizer. Participants will receive treatments through intravenous (IV) infusions during repeated cycles. The study has two parts: the first part focuses on checking safety and tolerance of PF-08634404 plus chemotherapy, while the second part compares PF-08634404 plus chemotherapy to atezolizumab plus chemotherapy to evaluate which works better. Some participants may continue receiving PF-08634404 alone after the initial treatment period. During the study, participants will have regular assessments including scans to measure tumor response, laboratory tests to monitor organ function, and evaluations of side effects. Researchers will track outcomes like overall survival, tumor response rate, progression-free survival, and quality of life using specific questionnaires. Safety monitoring will continue for up to 90 days after treatment. Participation may last for about two years after the last treatment dose for follow-up and outcome measurement.

Researchers are evaluating the combination of the investigational drug mevrometostat (PF-06821497) with enzalutamide compared to enzalutamide alone in men with metastatic castration-sensitive prostate cancer (mCSPC) who have not previously received androgen receptor pathway inhibitors or chemotherapy in this setting. This Phase 3, randomized, double-blind, placebo-controlled study aims to determine if the combination improves outcomes in participants who have only received limited prior therapy such as androgen-deprivation therapy or first-generation antiandrogens. Participants will be randomly assigned to one of two groups: one group will receive mevrometostat (875 mg twice daily) combined with enzalutamide (160 mg once daily), while the other group will receive a placebo twice daily plus enzalutamide (160 mg once daily). The study includes a Screening Phase, Randomization, Treatment Phase, Safety Follow-up, and Long-Term Follow-up. The treatment phase may last up to approximately 4 years, with ongoing safety and long-term assessment extending beyond this period. During the study, participants will be monitored through various evaluations including scans, blood tests, and patient-reported questionnaires assessing pain and quality of life. Researchers will measure outcomes such as radiographic progression-free survival, overall survival, prostate-specific antigen response, and adverse events, among others. Follow-up will continue for several years to assess long-term effects and disease progression, ensuring comprehensive safety and efficacy data collection throughout the trial.